bosentan anhydrous has been researched along with Coxsackie Virus Infections in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arner, A; Dou, Y; Garmaroudi, FS; Hegele, RG; Laher, I; Luo, H; Luo, Z; Marchant, D; McDonough, JE; McManus, BM; Si, X; Walker, E | 1 |
| Choy, JC; Laher, I; Lui, AH; McManus, BM; Moien-Afshari, F; Wei, K; Yanagawa, B | 1 |
2 other study(ies) available for bosentan anhydrous and Coxsackie Virus Infections
| Article | Year |
|---|---|
Bosentan enhances viral load via endothelin-1 receptor type-A-mediated p38 mitogen-activated protein kinase activation while improving cardiac function during coxsackievirus-induced myocarditis.
Topics: Animals; Antihypertensive Agents; Bosentan; Cardiac Output, Low; Coxsackievirus Infections; Disease Models, Animal; Endothelin A Receptor Antagonists; Enterovirus B, Human; Enzyme Activation; Humans; Mice; Myocarditis; p38 Mitogen-Activated Protein Kinases; Stroke Volume; Sulfonamides; Viral Load | 2009 |
Coxsackievirus B3 infection compromises endothelial-dependent vasodilation of coronary resistance arteries.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Bosentan; Coronary Vessels; Coxsackievirus Infections; Endothelin-1; Endothelium, Vascular; In Situ Nick-End Labeling; Male; Mice; Models, Cardiovascular; Myocarditis; Sulfonamides; Vasodilation; Vasodilator Agents | 2004 |